Does Bulimia's Bupropion Contraindication Apply to Binge Eating Disorder Without Purging?
The bupropion-in-bulimia seizure warning traces to purging, not to eating disorders as a category. This patient has binge eating disorder and has never purged in her life. Whether the label's actual wording — which doesn't distinguish the two — should still govern her case is a real test of whether a mechanism-based argument is allowed to override a diagnosis-based label.
L.G., a 38-year-old woman, has worked as a dental hygienist for fourteen years and jokes, not entirely joking, that she spends her days lecturing patients about their diets while quietly losing her own private battle with hers most nights after her two kids are in bed. She has tried, by her own count, six structured diet programs over the past decade, each producing modest short-term weight loss that reliably reversed within a year, a pattern she now recognizes — since her primary care physician screened her eight months ago and diagnosed binge eating disorder — as something closer to an unaddressed illness than a string of personal failures. Her binges follow a consistent shape: eating a large amount of food, usually while alone at night after the kids are down, with a clear sense that she cannot stop once it starts, followed by real shame the next morning. What has never once been part of the picture, across fourteen years of her own medical record and repeated, specific questioning by both her PCP and now this consultation, is any compensatory behavior — no vomiting, no laxative or diuretic use, no compulsive exercise. Her weight has climbed steadily rather than cycled, consistent with that history.
Her PCP referred her for this psychiatric consultation specifically because naltrexone-bupropion, an FDA-approved combination product for chronic weight management, is on the table, and the bupropion component carries a labeled contraindication for any current or prior diagnosis of bulimia nervosa or anorexia nervosa — wording that, read literally, doesn't actually name binge eating disorder at all, and doesn't stratify by whether purging behavior was ever present. The seizure signal behind that label traces to Horne and colleagues' 1988 finding of an elevated seizure rate in bupropion-treated bulimic patients, a population that was actively purging, with a proposed mechanism running through purging-induced electrolyte disturbance layered onto the drug's own dose-dependent seizure risk. L.G. has never purged, and her electrolytes today are unremarkable. The real question isn't only pharmacological. It's whether the field's own historical labeling decision — made at the level of diagnosis, not behavior, in an era before binge eating disorder was even a distinct formal diagnosis in its own right — should be read as silently including her simply because she shares a diagnostic category with bulimia in the broader "feeding and eating disorders" chapter, or whether the actual causal story the label was built on has nothing to do with her at all.
Psychiatric consultation, referred for pre-treatment ED screening
I don't think the bupropion contraindication meaningfully applies to L.G. Horne and colleagues' 1988 finding — the seizure signal behind this label in the first place — arose in a population that was actively purging, with a proposed mechanism running through purging-induced electrolyte disturbance layered on top of bupropion's own dose-dependent seizure risk. L.G. has never purged, in fourteen years of records and repeated direct questioning by two separate clinicians, and her electrolytes today are unremarkable. The label's diagnosis-based wording — "bulimia or anorexia nervosa" — predates binge eating disorder existing as its own formal diagnosis; it was never written with her specific presentation in mind, and the physiologic mechanism it was built on simply isn't present here.
I agree with the mechanism analysis on its own terms — I'm not disputing that the purging-specific causal story is real, or that her history genuinely doesn't include it. What I want to raise is a separate concern the seizure-mechanism question doesn't touch at all: naltrexone-bupropion is specifically a weight-management product, marketed and used to suppress appetite and drive weight loss. L.G. has an active binge eating disorder right now, not a resolved one. Using an appetite- suppressing drug to intentionally reduce her weight, in someone whose relationship with food already involves loss-of-control episodes, carries a real, separate risk of shifting her eating disorder's phenotype toward restriction — not because of a seizure, but because of what the drug is actually designed to do to her appetite and eating behavior.
I don't think the mechanism reasoning about seizures is wrong — I think it answers a narrower question than the one we actually need to answer before prescribing a weight-loss product to a patient with an active eating disorder.
I think you're each answering a different question, and both answers are right on their own terms. The seizure-mechanism argument is sound — I wouldn't withhold bupropion from L.G. on seizure grounds alone. But that resolves whether it's safe from a seizure standpoint, not whether this specific product is the right tool for her. Naltrexone-bupropion's studied dosing and titration protocol was developed in an obesity population without eating disorders in the picture at all — it wasn't designed or tested for someone with active binge eating disorder as its target population. If bupropion has a role for L.G., I'd want it justified on its own antidepressant or smoking-related merits, prescribed as bupropion on its own with careful ED-informed monitoring, rather than reached for as the pre-packaged weight-loss combination product specifically because the seizure logic happens not to apply to her.
Agreed: do not start naltrexone-bupropion at this visit. Refer L.G. for binge-eating-disorder- specific treatment — CBT, with consideration of an FDA-approved agent for binge eating disorder itself once she is engaged in behavioral treatment — before any weight-management medication decision is revisited. L.G. was told plainly that the seizure concern specifically does not apply to her history, so she understood the decision as being about treatment sequencing, not about her being considered at special medical risk.
Not agreed: whether naltrexone-bupropion should remain genuinely on the table later, once her binge eating disorder is in active treatment, or whether the Eating Disorder Therapist's phenotype- shift concern should rule it out indefinitely regardless of treatment status. The Clinical Pharmacologist sees no reason the combination product couldn't be reconsidered once her eating disorder is stabilized in treatment, since the seizure-mechanism objection was never really the barrier. The Eating Disorder Therapist is not persuaded that stabilization fully resolves the concern, given how directly the product's appetite-suppressing mechanism could still interact with binge eating disorder even in treatment. Left open, to be reassessed once L.G. has been in BED- specific treatment for a defined period.
Educational content only — a composite teaching case, not a real patient encounter or a substitute for clinical guidance. About These Cases →